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 ABSTRACT 
This study was conducted in Department of Biochemistry, 
Faculty of Veterinary Medicine. Samples were collected from Ahmed 
Gasim Hospital, Cardiac Surgery and Renal Transplantation Center, 
Haemodialysis Unit, in the period from April to May 2005, to 
determine the parathyroid hormone levels, total calcium levels and 
phosphorus levels in patients with chronic renal failure.  
Fourty patients with chronic renal failure were selected for 
this study. Their ages range from (18-78 years), including 31 males, 9 
females, the duration of dialysis ranged from (6-48 months).  
The study also included 20 healthy personnel subjects as 
control group.  
Sera were analyzed for parathyroid hormone concentration, 
total calcium concentration and phosphorus concentration.   
The results showed that the parathyroid hormone level was 
significantly (P <0.05) increased in the patients group compared to 
the control.  
Total calcium concentration was significantly (P<0.05) 
decreased in the patients group compared to the control, 57.5% with 
hypocalcemia, 20% within the normal range and 22.5% with 
hypercalcemia. Phosphorus concentration was significantly (P<0.05) 
increased in the patients group compared to the control, 52.5% were 
within the normal range, 47.5% with increased level 
(hyperphosphatemia), and no one observed with hypophosphatemia.  
 
 
 
 
 
 
 
 
 
 
  
 
  ﻤﻠﺨﺹ ﺍﻷﻁــﺭﻭﺤـﺔ
ﻭﻗـﺩ ﺘـﻡ ﺠﻤـﻊ . ﻓﻰ ﻗﺴﻡ ﺍﻟﻜﻴﻤﻴﺎﺀ ﺍﻟﺤﻴﻭﻴﺔ ﻜﻠﻴﺔ ﺍﻟﻁﺏ ﺍﻟﺒﻴﻁﺭﻱ ﺃﺠﺭﻴﺕ ﻫﺫﻩ ﺍﻟﺩﺭﺍﺴﺔ 
 ﻭﺤﺩﺓ ﻏﺴﻴل ﺍﻟﻜﻠـﻰ ، ﻓـﻰ -ﻤﺭﻜﺯ ﺠﺭﺍﺤﺔ ﺍﻟﻘﻠﺏ ﻭﺯﺭﺍﻋﺔ ﺍﻟﻜﻠﻰ - ﻤﺴﺘﺸﻔﻰ ﺃﺤﻤﺩ ﻗﺎﺴﻡ ﺍﻟﻌﻴﻨﺎﺕ ﻤﻥ 
ﻡ، ﺒﻐﺭﺽ ﺘﺤﺩﻴﺩ ﻤﺴﺘﻭﻴﺎﺕ ﺍﻟﻬﺭﻤﻭﻥ ﺍﻟﺠﺎﺭ ﺩﺭﻗﻰ ﻟـﺩﻯ ﻤﺭﻀـﻰ 5002ﺍﻟﻔﺘﺭﺓ ﻤﻥ ﺃﺒﺭﻴل ﺇﻟﻰ ﻤﺎﻴﻭ 
  . ﻜﻠﻭﻯ ﺍﻟﻤﺯﻤﻥﺍﻟﻔﺸل ﺍﻟ
 ﻤﺭﻴﺽ ﺒﺎﻟﻔﺸل ﺍﻟﻜﻠﻭﻯ ﺍﻟﻤﺯﻤﻥ، ﺘﺘﺭﺍﻭﺡ ﺃﻋﻤﺎﺭﻫﻡ ﻤﺎ ﺒﻴﻥ 04ﻫﺫﻩ ﺍﻟﺩﺭﺍﺴﺔ ﺃﺠﺭﻴﺕ ﻋﻠﻰ 
 84 - 6 ﻤﻥ ﺍﻹﻨﺎﺙ، ﻤﺩﺓ ﺍﻟﻐﺴﻴل ﻟﺩﻴﻬﻡ ﻜﺎﻨﺕ ﻤـﺎ ﺒـﻴﻥ 9 ﻤﻥ ﺍﻟﺫﻜﻭﺭ ﻭ 13 ﺴﻨﺔ، ﺸﻤﻠﺕ 67-81
  .  ﺸﺨﺹ ﺃﺼﺤﺎﺀ ﻜﻤﺠﻤﻭﻋﺔ ﻤﺭﺍﻗﺒﺔ02ﺸﻬﺭ ﻭﺸﻤﻠﺕ ﺍﻟﺩﺭﺍﺴﺔ ﺃﻴﻀﺎﹰ 
ﻤـﻭﻥ ﺍﻟﺠـﺎﺭ ﺍﻟـﺩﺭﻗﻰ ﻭﺍﻟﻜﺎﻟـﺴﻴﻭﻡ ﺍﻟﻜﻠـﻲ ﺘﻡ ﺃﺨﺫ ﻋﻴﻨﺎﺕ ﺍﻟﺩﻡ ﻟﺩﺭﺍﺴﺔ ﻤﺴﺘﻭﻴﺎﺕ ﻫﺭ 
  : ﻭﺍﻟﻔﻭﺴﻔﻭﺭ ﺤﻴﺙ ﻜﺎﻨﺕ ﺍﻟﻨﺘﺎﺌﺞ ﻋﻠﻰ ﺍﻟﻨﺤﻭ ﺍﻟﺘﺎﻟﻲ
ﻜﺎﻥ ﻫﻨﺎﻙ ﺍﺭﺘﻔﺎﻉ ﻤﻠﺤﻭﻅ ﻓﻰ ﻜل ﻗﻴﻡ ﻤﺴﺘﻭﻴﺎﺕ ﺍﻟﻬﺭﻤﻭﻥ ﺍﻟﺠﺎﺭ ﺩﺭﻗﻰ ﺒﻤﺘﻭﺴـﻁ  •
  .  .)L/lom p 554 ± 5411(ﻗﺩﺭﻩ            
ﺤﻴـﺙ  )ld/gm 3.2 ± 4.6(ﺃﻤﺎ ﺒﺎﻟﻨﺴﺒﺔ ﻟﻠﻜﺎﻟﺴﻴﻭﻡ ﺍﻟﻜﻠﻰ ﻓﻜﺎﻥ ﻤﺘﻭﺴﻁ ﺍﻟﻘـﻴﻡ  •
  ﻓﻔﻰ ﺍﻟﻤـﺴﺘﻭﻯ ﺍﻟﻁﺒﻴﻌـﻲ ﻭ  %02ﻤﻨﻬﻡ ﻟﺩﻴﻪ ﺍﻨﺨﻔﺎﺽ، ﺃﻤﺎ  %5.75ﺤﻅ ﺃﻥ ﻟﻭ
  .  ﺘﻭﺠﺩ ﻟﺩﻴﻬﻡ ﺯﻴﺎﺩﺓ ﻓﻰ ﻤﺴﺘﻭﻯ ﺍﻟﻜﺎﻟﺴﻴﻭﻡ ﺍﻟﻜﻠﻲ%5.22
ﺤﻴﺙ ﻴﻭﺠﺩ ﺍﺭﺘﻔـﺎﻉ   )ld/gm 1.2 ± 4.5(ﺃﻤﺎ ﺒﺎﻟﻨﺴﺒﺔ ﻟﻠﻔﺴﻔﻭﺭ ﻓﻤﺘﻭﺴﻁ ﺍﻟﻘﻴﻡ  •
 ﻓﻬﻰ ﻓﻰ ﺍﻟﻤﺴﺘﻭﻯ ﺍﻟﻁﺒﻴﻌﻴﺔ ﻭﻟﻡ ﻴﻼﺤﻅ ﺃﻯ ﺍﻨﺨﻔﺎﺽ  %7.25 ﺃﻤﺎ  %5.74ﻋﻨﺩ  
  . ﺎﺕﻓﻰ ﺍﻟﻤﺴﺘﻭﻴ
  . ﺘﻤﺕ ﻤﻘﺎﺭﻨﺔ ﺠﻤﻴﻊ ﺍﻟﻤﺴﺘﻭﻴﺎﺕ ﺍﻟﺴﺎﺒﻘﺔ ﻤﻊ ﻤﺠﻤﻭﻋﺔ ﺍﻟﻤﺭﺍﻗﺒﺔ •
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INTRODUCTION 
 
Chronic renal failure (CRF) produces a number of 
abnormalities of calcium and phosphorus metabolism. Secondary 
hyper-parathyroidsm develops early in the course of chronic renal 
insufficiency (Arnaud, 1974), even at the glomerular filtration rate 
(GFR) of 50-80ml/1.73m2 (Malluche, et al. 1976).  
Secondary hyperparathyroidism is generally thought to 
result from hypocalcemia as a result of phosphate retention and 
deficient 1,25  (OH)2D3  synthesis (Salusky, et al.1987). 
 Inresponse to an increase in serum phosphorus 
concentration, production of 1,25 (OH)2D3  is decreased and secretion 
of parathyroid hormone (PTH) is increased, which in turn increases 
urinary excretion of serum phosphorus to maintain normal serum 
calcium and phosphorus  level. Therefore, PTH is an important factor 
in the regulation of calcium and phosphorus metabolism and the key 
target organ of parathyroid hormone action are the kidney and 
skeleton (Hruska and Khan, 2000). Without treatment the severity of 
secondary hyperparathyroidism generally worsens with progressive 
decline in renal function (Rahman, et al. 2005). 
In Sudan, data regarding parathyroid hormone in relation to 
different biochemical parameters in patients with chronic renal 
failure are not available.  
Therefore, this study was conducted to estimated 
parathyroid hormone levels and to correlate these levels with other 
biochemical parameters, such as total calcium and phosphorus, and 
also to correlate the levels of the PTH with other factors such as age 
and duration of dialysis.  
 
 
 
 
 
 
 
 
LITERATURE REVIEW 
1.1. Parathyroid hormone:  
1.1.1. Anatomy and Synthesis: 
Normally there are four parathyroid glands in the human 
being, they are located immediately behind the thyroid gland, one 
behind each of the upper and each of lower poles of the thyroid 
(Gyton and Hall, 1996).  
Parathyroid hormone has been isolated in a pure form. It is 
first synthesized on the ribosomes in the form of a prepro hormone, a 
polypeptide chain of 110 amino acids residues. This is cleaved first to 
a prohormone with 90 amino acids, then to the hormone itself with 84 
amino acids residues by the endoplasmic reticulum and golgi 
apparatus, and finally packaged in secretory granules in the 
cytoplasm of the cells. The final hormone has a molecular weight of 
about 9500. Smaller compounds with as few as 34 amino acids 
residues adjacent to the N terminus of the molecule have also been 
isolated from the parathyroid glands that exhibit full parathyroid 
hormone activity. In fact, because the kidneys rapidly remove the 
whole 84-amino acids hormone within minutes but fail to remove 
many of the fragments for hours, a large share of the hormonal 
activity is caused by the fragments (Gyton and Hall, 1996). 
1.1.2. Control of parathyroid hormone secretion:  
The parathyroid glands are not under anterior pituitary 
control nor under nervous control. The main mechanism known to 
regulate PTH release is a negative feedback with plasma ionized 
calcium (Ca+2). A decrease in plasma Ca+2 level stimulates the 
parathyroids to release PTH. Conversely an increased plasma ionized 
calcium level decreases hormonal release (Sukkar, et al. 2000) (see 
Fig.1).  
Many other factors are known to influence PTH secretion, 
including β-adrenergic agonists, vitamin D metabolites, growth 
hormone and somatostatin, vitamin A, prostaglandin, prolactin, 
aluminum, and divalent cations such as magnesium and strontium 
(Weatherall, et al. 1996).  
 
 
1.1.3. Parathyroid hormone action:   
    Parathyroid hormone increases ionized plasma calcium and 
lowers plasma phosphate concentration. It acts on the bone and 
kidney and indirectly on the gastrointestinal tract (see Fig.1). Its 
actions on the bone and kidney appear to be medicated by cAMP. 
PTH increases the rate of bone reabsorption by stimulating the 
activity of the osteocytes and osteoclasts. The presence of vitamin D 
is needed for these actions. These effects are important in long-term 
regulation of plasma calcium while its actions on the kidney appear 
to be more important in compensating for short-term changes (Bray,  
et al. 1994).   
In the kidney, PTH increases the tubular reabsorption of 
calcium and decreases that of phosphate. The resulting fall in plasma 
phosphate stimulates calcium release from bone and prevents the 
deposition of calcitriol in the kidney. Thus, the absorption of calcium 
in the gastrointestinal tract is increased as a consequence of an 
increase in calcitriol. In the long-term, increased secretion of PTH 
may result in a net loss of calcium from the body through the kidney. 
Under these conditions, increased ionized plasma calcium increases 
the filtered load by an amount that exceeds the additional calcium 
reabsorbed in the tubules (Bray, et al. 1994).  
1.2.Calcium in the body:  
Calcium is an important intra-and extra-cellular ion, which 
comprises a major component of the skeleton and is needed for blood 
cloting and for the activity of many enzyme systems. Movement of 
calcium across cell membranes occurs all the time and change in flux 
is an important event, with physiological consequences. The 
importance of changes in calcium within the cell, acting as a 
messenger for hormones. Release of calcium within the cell can be an 
important intra-cellular signal, leading, for example, to activation of 
secretion processes or to muscular contraction. Even small alterations 
in extra-cellular calcium concentration  affect the excitability of cells, 
and a low serum calcium concentration, hypocalcaemia, can lead to 
epilepsy or tetany (Brook and Marshall, 1996).  
 
 
1.3. Effect of parathyroid hormone on calcium and 
phosphate Concentrations in the extra- cellular fluid:  
The rise in calcium concentration is caused principally by two 
effects:  
1- An effect of parathyroid hormone in causing calcium and 
phosphate absorption from the bone.  
2- A rapid effect of parathyroid hormone in decreasing the 
excretion of calcium by the kidneys. The decline in phosphate 
concentration, on the other hand, is caused by a strong effect of 
parathyroid hormone on the kidneys in causing excessive renal 
phosphate excretion, an effect that is usually great enough to 
over ride increased phosphate absorption from the bone 
(Gyton and Hall, 1996). 
 
 
 
 
 
 
 
 
  
Fig. (1): Factors involved in plasma calcium homeostasis 
 
1.4. Vitamin D:  
Vitamin D is a steroid pro-hormone. It is represented by 
steroids that occurs in animals, plants and yeast. By various 
metabolic changes in the body, they give rise to a hormone known as 
calcitriol, which plays a central role in calcium and phosphate 
metabolism (Murray, et al 1996).   
Ergocalciferol (vitamin D) may be made commercially from 
plants in this way, whereas, in animals, cholecalciferol (vitamin D3)  
is formed from 7- dehydrocholesterol in exposed skin (Murray, et al. 
1996).   
Vitamin D3 formed from 7-dehyrocholesterol by the action of 
sunlight, and dietary vitamin D3 (or D2), after absorption from cells 
in the intestine followed by transport in the lymphatics, circulates in 
the blood bound to a specific globulin, vitamin D-binding protein. 
Vitamin D3 is taken up by the liver, where it is hydroxylated on the 
25 positions by vitamin D3-25 hydroxylase.  25-hydroxy vitamin D3 
is the major form of vitamin D in the circulation and the major 
storage form in the liver (Adams, 1982).  
In the renal tubules, bone and placenta, the 25-hydroxy 
vitamin D3 is further hydroxylated in position 1 by 25-hydroxy 
vitamin D3-1-hydroxylase, a mitochondrial enzyme. The product is  
1α, 25-dihydroxy vitamin D3 (calcitriol) (Murray, et al .1996).  
 
1.4.1. Vitamin D action: 
In addition to increasing calcium absorption from the 
intestine, 1,25-dihydroxycholecalciferol facilitates calcium 
reabsorption by the kidneys. It also acts on bone, where it mobilizes 
calcium and phosphate, by increasing the number of mature 
osteoclasts. It also stimulates osteoblasts, but the net effects are still 
calcium mobilization (see Fig. 1) (Ganong, 1997).  
1.5. Chronic renal failure: 
 Renal failure is a common problem world wide, it is now 
more frequent in Sudan. One of the most important function of the 
kidney is the endocrine and metabolic function. This is done in 
association with parathyroid gland. Chronic renal failure (CRF) is 
defined as a persisting and progressive deterioration of renal 
function leading to retention of waste products of metabolism 
(Brenner, et al. 1998).  
Chronic renal failure is complicated by hypertension, 
bleeding tendency due to defect on platelets function, severe anaemia 
due to bone marrow supression and/or erythropoietin deficiency, 
infection, hyper- uricemia, hyperphosphatemia and hyperkalemia 
(Brenner, et al. 1998).  
The management of CRF is mainly directed towards the 
underlying cause, so as to delay the progression of renal damage, and 
the complications (Brenner, et al. 1998).  
1.6. Hyper-parathyroidism: 
The term hyperparathyroidism is applied to those clinical 
disorders characterized by an increase in circulating concentration of 
PTH. These can be arbitrarily classified into primary, secondary, 
tertiary and ectopic (Pseudo-) hyperparathyroidism (Weatheral, et al. 
1996). 
1.6.1. Secondary hyper-parathyroidism: 
It is due to hypo-calcaemia, such as seen in vitamin D 
deficiency or chronic renal failure, which results in the over secretion 
of PTH and lead to hyperplasia of the parathyroid glands (Weatheral, 
et al. 1996). 
 
 
 
1.6.1.1. Control of parathyroid hormone secretion in secondary 
hyperparathyroidism: 
In secondary hyper-parathyroidism, hyper function of the 
parathyroid glands is the result not of an abnormality of the glands 
themselves but of continued stimulation by low concentration of 
calcium ion in the circulatory system. This could result from 
excessive losses of calcium in the urine, feces, or sweat, insufficient 
dietary intake of calcium or inadequate calcium absorption from the 
intestine, or decreased translocation of calcium from the solid 
calcium (Prient, et al. 1976). 
The store of the PTH in the parathyroid glands is small in 
relation to the amount secreted. For example, in human beings 
normal parathyroid glands contain less than 500 units/g of fresh 
tissue (Kenny, et al.1964). Normal parathyroid glands in aggregate 
usually weight less than 150 mg (Roth, 1962).  
The storage capacity of the parathyroid glands for PTH is low 
and the turnover of hormone is high, the parathyroid glands must 
increase the rate of hormone synthesis and release per cell as well as 
increase the number of cells involved to meet the demands of the 
chronic stimulation of hypocalcemia (Prien, et al. 1976).  
Factors to be considered in control of the rate of synthesis of 
PTH per cell are rate of entry of amino-acid precursors into the cell, 
rate of incorporation of amino acids into polypeptide chains, 
conversion of possible prohormone to active hormone, transport of 
active hormone within the cell packaging, and secretion. If increased 
synthesis is not adequate to meet the demands of chronic stimulation, 
more cells would have to be recruited (Prien, et al. 1976).  
In view of the small amount of hormone stored in the 
parathyroid glands, persistent hypocalcemia might be expected to 
result in increased mass or volume of the parathyroid gland (Stoerk 
and Carnes, 1945), although such an increase in itself would not be 
sufficient to conclude that the glands are hyperfunctioning. There is 
evidence, however, that secondary hyperfunction in human beings 
and secondary hyperfunction induced experimentally in animals is 
characterized by an increase in relative and absolute numbers of chief 
cells, an increase in the ratio of cells to interstitum, increased ratios of 
cytoplasm to nucleus (Capen, et al.1968). An absence of or marked 
decrease in fat is a characteristic of secondary hyperplasia of the 
parathyroid glands in human beings (Roth, 1962). 
 The biosynthetic activity of the parathyroid cells can be 
estimated by evaluating the secondary state of the changes in 
structure which are presumably related to function (Prien, et al. 
1976).  
The question may now be asked whether in secondary hyper -
parathyroidism the increase in total mass and number of cells is 
accompanied by augmented synthesis and release of PTH. There is 
evidence of several different types that parathyroid tissue in 
secondary hyper parathyroidism responds qualitatively as expected 
to alterations in ionic environment (Prien, et al. 1976).  
Parathyroid tissue from patients with the secondary hyper-
parathyroidism of chronic renal failure, when cultured in vitro, 
decreases the release of PTH in response to increasing the calcium 
and/or magnesium concentration in the ambient medium 
(Sherwood, et al.1969).  
In secondary hyper-parathyroidism the increase in number of 
active cells may be accompanied by alterations in parathyroid 
function as assessed quantitatively (Prien, et al. 1976). It has been 
noted that the number of secretory granules in active parathyroid 
cells decrease rather than increase when parathyroid tissue in culture 
is switched abruptly from high calcium to a low calcium 
environment (Roth and Raisz, 1966).  
Since the amount of stored hormone is small, then a cell 
already releasing hormone at high rate may not be able to release 
much more when the ambient calcium concentration is lowered. 
Since the total number of cells is also increased the net effect on 
hormone release by increasing the hypocalcemia is not readily 
predictable (Prien, et al. 1976).  
Evidence suggests that the chronic stimulus of hypocalcemia is 
responsible for the increase in parathyroid cell mass as well as 
hyperfunction of each cell in secondary hyper-parathyroidism 
(Melson, 1966).  
In secondary hyper-parathyroidism in human beings the 
increase in parathyroid mass is guide variable and ranges from slight 
increases to weights over 100 times normal (over 10 g) (Prien, et al, 
1976).  
1.7. Hypocalcemia in chronic renal failure: 
The biochemical mechanisms involved in the pathogenesis of 
the disturbances of calcium regulation and their effects in causing 
metabolic bone disease in patients with chronic renal failure are 
multi-factorial and still require considerable further elucidation 
(Wills, 1971).  
Chronic renal failure leads to the retention of metabolic end-
products, and on the main line this leads to the development of 
acquired vitamin D resistance with consequent hypocalcaemia. The 
latter is responsible for both osteomalacia and parathyroid gland 
stimulation. The response of the parathyroid glands with increased 
hormone secretion causes osteitis fibrosa. However, in some patients 
the efficacy of parathyroid hormone action is blocked either as a 
result of the acquired vitamin D resistance or because of the marked 
degree of hypocalcaemia. It would seem probable that the resistance 
to parathyroid hormone action results in excessive parathyroid 
hormone secretion, (parathyroid hormone overdosage), and 
osteosclerosis. As associated features of the retention of metabolites 
in chronic renal failure there is both metabolic acidosis with bone 
dissolution and phosphate retention (Wills, 1971).  
The absence of tetanic episodes in patients with chronic renal 
failure and hypocalcemia is classically explained by the concomitant 
acidosis, the protective role of acidosis has been attributed either to 
an increase in the concentration of the ionized calcium due to a 
decrease in the protein-bound fraction or to a specific effect of 
hydrogen ion on neuromuscular irritability(Walser,1962).  
In addition to both osteomalacia and osteitis fibrosa, patients 
with chronic renal failure also show osteosclerosis, which was 
probably the most common bone lesion seen in chronic renal failure, 
and may be present simultaneously with either osteomalacia or 
osteitis fibrosa (Kaye and Silverman, 1965). 
The bone lesions in these patients are seen histologically as 
an excess of bone, or hyperostosis, rather than the production of 
abnormally dense bone (Garner and Ball, 1966).  
1.8. Hyperphosphatemia in chronic renal failure:  
In chronic renal failure the plasma phosphate concentration 
rises. Plasma inorganic phosphate is derived from the diet and may 
be liberated from organic compounds such as phospholipids and 
nucleoproteins in catabolic states. The increase in the plasma 
concentration could be considered to be due simply to a reduction of 
functional renal mass. Although phosphate clearance decreases with 
advancing chronic renal disease the rate of clearance falls 
proportionately less than of glomerular filtration. Thus the average 
rate of phosphate excretion per residual nephron increases as the 
nephron population is reduced. There is evidence that in this 
mechanism parathyroid hormone is the important factor rather than 
the increase in glomerular filtration per residual nephron (Wills, 
1971). The high phosphate concentration in itself is not known to 
produce biochemical disturbances but, in the classical concept of 
bone disease in chronic renal failure, phosphate is considered to have 
a secondary effect in lowering the plasma calcium concentration. It is 
well accepted that oral or intravenous administration of phosphate 
salts lowers the plasma calcium concentration in both normal and 
hypercalcaemic subjects (Wills, 1971).            
    
 
MATERIALS AND METHODS 
 
2.1. The study area and population: 
This study was conducted in Khartoum State in Ahmed 
Gasim Hospital, in the period from April to May 2005. Fourty 
patients with chronic renal failure were selected randomly from 
Haemodialysis Unit. All patients underwent dialysis two times 
weekly, four hours per session, and treated with vitamin D sterol and 
calcium supplementation. The study also included 20 normal subjects 
as control group. 
2.2. Sample collection:  
Blood samples were obtained after an overnight fast. All 
samples were drawn immediately before the dialysis session.  Five ml 
of venous blood were taken from antecubital vein by plastic 
disposable syringes. The blood was then transferred into a plane 
glass tubes. After one hour at room temperature (after clot retraction) 
centrifugation of the blood was done at a relative centrifugal force of 
1000 g for 5 minutes. Afterward, sera were removed by disposable 
pasture pipettes and transferred into glass containers. Sera were 
stored at (-20°C) to be analyzed in patches.  
2.3. Biochemical analysis:  
2.3.1. Parathyroid hormone determination:  
Parathyroid hormone is determined by using 
radioimmunoassay (RIA) kit (M-44-68). 
2.3.1.1. Principle:  
The RIA method incorporated a competitive-binding reaction 
in which a fixed amount of radiolabeled antigen and antigen in the 
samples compete, for limited number of specific antibody-binding 
sites. Both unlabeled and radiolabeled antigens are bound by the 
antibody forming percipitable complexes. Bound and free 
radiolabeled antigens must then be separated before the radioactivity 
of the bound radioisotope can be measured (Yalow, 1993). 
2.3.1.2. Reagents: 
RIA China kit consisting of 6 vials of parathyroid hormone 
standards: standards are prepared by adding 2.0 ml incubation 
solution and mixed by gentle inversion, ready to be used with known 
concentration of parathyroid hormone (63.5, 176.3, 352.6, 705.2, 1763 
and 3526 p mol/L) respectively. 
  
•  One vial of I125 - PTH solution.   
•  One vial incubation solution.   
•  One vial antibody solution.   
•  One vial precipitate solution.   
2.3.1.3. Equipments:  
1- Micropipettes with disposable tips (10 - 100 µL).  
2- Test tubes and Vortex mixer.  
3- Test tube racks. 
4- Incubater.  
5- Centrifuge. 
6- Gamma counter suitable for measuring iodine-125.  
2.3.1.4. Procedure:  
1- The tubes were  labeled in duplicates .  
2- 100 µL of each standard (STD) and samples were pipetted, 100µL 
of incubation solution were added to zero STD tube and 200 µL of 
incubation solution were added to non specific binding (NSB) tube. 
Then 100 µL  of     I125 -  labeled    PTH were added to each tube and 
100 µL  of PTH antibody were added to zero STD and STDs and 
samples, as  Seen in the following table:  
 Total NSB OSTD STD 1-6 Samples 
Incubation solution  - 200 100 - - 
Standard solution  - - - 100 - 
Samples  - - - - 100 
I125 - labeled PTH 100 100 100 100 100 
PTH antibody  - - 100 100 100 
 
3- The tubes were mixed and incubated at 4 C° for 16 hours.  
4- 500 µL of cold precipitate were added to each tube and mixed.  
5- The tubes were centrifuged for 15 minutes at 3000 g.  
6- The bound fractions were separated from the free fractions by 
decantation.  
7-  The precipitates were counted in gamma counter.  
2.3.1.5. Calculations:  
Results were calculated by using automated computerized 
method. 
The method: using logit-log plotting:  
i. Express the counts B for each of the standards and 
unknown as a percentage of the mean counts of zero 
standards (B0).  
ii. B/B0% = B standard or unknown  × 100%  
                                     B0  
iii. Plot the percentage values obtained for the PTH concentration 
on logit-log graph paper and construction as standard curve.  
iv. Read the PTH concentration directly from curve of unknown 
samples. 
 
 
 
                                                        Concentration of antibody 
 
 
 
 
 
B/B0  
2.3.2. Total serum calcium determination:  
Total calcium was determined by the method described by 
(Connerty, et al. 1966).  
2.3.1. Principle: 
The method is based on the specific binding of cresolftalein 
complexone (OCC), a metallochromic indicator, and calcium at 
alkaline pH with the resulting shift in the absorption wavelength of 
the complex. The intensity of the cromophore formed is proportional 
to the concentration of total calcium in the sample.  
OCC + Calcium         pH 10.7        OCC-calcium complex 
2.3.2.2. Working reagent: 
R1: occ indicator. 
R2: occ buffer. 
One volume of R1 were added to one volume of R2 and mixed.  
2.3.2.3. Procedure:  
1- Reagents and samples were brought at room temperature.  
2- They were pipetted into labeled test tubes as it is shown in the 
following table:  
 
Tubes Blank Samples STD 
Working reagent  1.0 ml 1.0 ml 1.0 ml 
Samples  _ 10 µL - 
STD  - - 10 µL 
 
3- The tubes were then mixed and incubated at room temperature for 
2 minutes.  
4- The absorbance (A) of the sample and STD were read against 
blank reagent at 570 nm using a colorimeter. 
2.3.2.4. Calculations:  
       Total serum calcium (mg/dl) =  A of sample    × STD concentration    
                                                           A of STD  
2.3.3. Serum phosphorus determination:  
Serum phosphorus was determined by the method described 
by  (Drewes , 1972). 
2.3.3.1. Principle: 
Inorganic phosphate reacts with molybdic acid forming a 
phosphomolybdic complex. Its subsequent reduction in alkaline 
medium originates a blue molybdenum colour with intensity 
proportional to the amount of phosphorus present in the sample.  
P3- O4 + H+ + (NH4)6 MO7O24       Pi         Phosphomolybdic complex  
Phosphomolybdic complex    pH >10    Molyodenum blue  
                                                    reductant 
2.3.3.2. Working reagent: 
R1: Molybdate Reagent. 
R2: Reducing solution. 
R3: Color developer. 
One volume of R1 were added to one volume of R2 and mixed.  
2.3.3.3. Procedure:  
1- Reagents and samples were brought at room temperature. 
2- They were pipetted into labeled test tubes as it is shown in the 
following table:  
Tubes Blank Samples STD 
Working reagent  1.0 ml 1.0 ml 1.0 ml 
Samples  _ 50 µ L - 
STD  - - 50 µ L 
 
3- The tubes were mixed and incubated at room temperature for 1 
minute.  
4- 0.5 ml of developer (R3) were added to each tube. 
5- The absorbance of the sample and the STD were read against 
blank reagent at 740 nm using a colorimeter. 
2.3.3.4. Calculations:   
                 Phosphorus  (mg/dl) =  A of sample    × STD concentration    
                                                           A of STD  
2.4. Data analysis: 
Clinical data were collected through a questionnaire sheet. 
Parathyroid hormone, total serum calcium and phosphorus were 
obtained from the laboratory.  
The percentage of ages, sex and duration of dialysis were 
analyzed as seen in the appendex (Table 3, Figures 6 and 7).  
Relation between parathyroid level and total calcium level, 
phosphorus level, ages and duration of dialysis were studied. 
2.5. Statistical analysis: 
All the data were presented as the mean ±SD. Student t-test 
was used to evaluate the statistical significance of various parametrs 
and (P. value) of ≤ 0.05 was considered significant (Babiker, 2001). 
 
RESULTS  
 
In this study a total of 40 patients with chronic renal failure in 
the haemodialysis unit at Ahmed Gasim Hospital, Cardiac and Renal 
Transplantation Center were examined for the serum level of PTH, 
total calcium and phosphorus. The study also included 20 healthy 
personnel subjects as control group. 
3.1. Serum parathyroid hormone: 
In this study, it was found that the parathyroid hormone level 
was high in all chronic renal failure patients (Table 1).As shown in( 
Table 2) the level of parathyroid hormone is significantly  (P<0.05) 
higher in the patients group compared to the control group. No 
significant correlation between PTH level and age (Fig. 1), and PTH 
level and duration of dialysis was found (Fig. 2).  
 
 
 
 
 
 Table (1): The level of PTH, total calcium and phosphorus   
   in patients with chronic renal failure 
High Serum level  Normal Low serum level  
Parameters 
N % N % N % 
% 
PTH  (n = 40) 40 100 - - - - 100 
Total calcium  
(n = 40) 
9 22.5 8 20 23 57.5 100 
Phosphorus 
(n = 40) 
19 47.5 21 52.5 - - 100 
 
 
Table (2): The level of parathyroid hormone 
total calcium and phosphorus in chronic renal failure patients 
compared to  control group 
Parameters 
CRF patients  
(mean ± SD) 
Control group
(mean ± SD) 
National reference 
range 
PTH (P mol/l)  1145 ± 455a 83 ± 30b 70 – 100 
Total calcium (mg/dl) 6.4 ± 2.3a 9.4 ± 1.6b 8.4 – 10.4 
Phosphorus  (mg/dl) 5.4 ± 2.1a 3.2 ± 0.4b 2.7 – 4.5 
 
Means within the same raw having different superscript letters are 
significantly different (P <0.05).  
 
 
Fig. 2. Corerelation between parathyroid hormone level and age in patients with 
chronic renal failure 
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Fig. 3. Corerelation between parathyroid hormone level and duration of dialysis
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3.2. Serum total calcium: 
In the chronic renal failure patients hypocalcaemia was found in 
57.5%              (Table 1). As shown in ( Table 2) the level total calcium 
concentration was significantly  (P<0.05) lower in the patients group 
compared to the control group .Also no significant correlation 
between total calcium level and parathyroid hormone level (Fig. 3).  
3.3. Serum phosphorus: 
In the chronic renal failure patients hyperphosphatemia was found in 
47.5%  (Table 1). As shown in (Table 2) the level of serum phosphorus 
concentration was significantly  (P<0.05) higher in the patients group 
compared to the control group. Also no significant correlation 
between phosphorus level and parathyroid hormone level (Fig. 4).  
 
 
Fig. 4. Corerelation between parathyroid hormone level and total Ca in  patients with cronic 
renal failure 
0
500
1000
1500
2000
2500
2 2.4 4.1 4.4 5.6 5.6 5.8 6.7 6.8 7.1 7.8 8.3 9.3 11
.2
12
.2
14
.1
Total Ca (mg/dl) 
PT
H
 (p
m
ol
/L
) 
 
 
 
Fig. 5: Corerelation between parathyroid hormone level and total phosphorus (P) in patients with 
chronic renal failure  
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DISCUSSION 
The present study was undertaken to assess PTH in patients 
with chronic renal failure and to correlate the levels with other 
biochemical parameters such as total calcium and phosphorus.  
 In this study; it was observed that plasma PTH was 
significantly increased in patients with chronic renal failure as 
compared to the control group. Sherrard, (1993) reported secondary 
hyperparathyroidism is a common finding in dialysis patients. In this 
study, significant levels of hypocalcemia and hyperphosphaatemia 
were present in patients with chronic renal failure. This in line with 
Hruska et al., (1975) who reported about hypocalcemia resulting from 
phosphate retention and calcium malabsorption which has been 
shown to cause over production of parathyroid hormone (PTH) in 
advanced renal disease.  
In early renal failure, alterations in vitamin D metabolism play 
a key role in the development of secondary hyperparathyroidism. 
Low levels of calcitriol and decreased expression of the vitamin D 
responsive element may allow greater synthesis and secretion of 
PTH. Phosphorus independent of serum calcium and calcitriol 
increases PTH synthesis and secretion by a post-transcriptional 
mechanism (Slatopolsky, et al. 1999).   
 A prolonged decrease in serum Ca2+ and 1,25 (OH)2D3, or 
increase in serum phosphorus, such as in patients with chronic renal 
failure, leads to the appropriate secondary increase in serum PTH. 
This secondary hyperparathyroidism involves increases in PTH gene 
expression, synthesis, and secretion, and if chronic, to proliferation of 
the parathyroid gland (PT) cells. Low serum Ca2+ leads to an increase 
in PTH secretion, PTH mRNA stability, and PT cell proliferation. 
Phosphate also regulates the PT in a similar manner. The effect of 
Ca2+ on the PT is mediated by a membrane Ca2+ receptor. 
1,25(OH)2D3 decreases PTH gene transcription. Ca2+ and phosphate 
regulate the PTH gene posttranscriptionally by regulating the binding 
of PT cytosolic proteins (Silver, et al. 2002). 
In secondary hyperparathyroidism there is down regulation of 
the calcium receptor (CaR) protein, and for any increase in serum 
Ca2+ there is a less efficient inhibition of PTH secretion. As a result, 
for a particular serum Ca2+ concentration there is an enhanced 
secretion of PTH, which is the essence of the so-called "shift" in the 
Ca2+-PTH set point of secondary hyperparathyroidism. This CaR 
downregulation occurs in the secondary hyperparathyroidism of 
chronic renal failure (Brown, et al. 1995, Kifor, et al. 1996). 
The PT has a limited amount of preformed secretory granules 
containing mature PTH. The PTH in these granules is itself under 
regulatory control. In the face of persistent hypercalcemia, there is a 
rapid degradation of the mature PTH in the PT cell. With the 
stimulus of hypocalcemia there is a rapid secretion of PTH that is 
rapidly renewed by the synthesis of new hormone. It has been shown 
that the mechanism of this regulation in vivo to be mainly 
posttranscriptional by an increase in PTH mRNA stability (Kilav ,et 
al.1995, Moallem,          et al. 1998). This is in contrast to the effect of 
1,25(OH)2D3 to markedly decrease PTH gene expression, which is a 
transcriptional effect (Silver, et al.1986). It was shown in vitro that 
1,25(OH)2D3 decreases PTH gene expression, and in the following 
year  shown in vivo in rats that 1,25(OH)2D3 dramatically decreased 
PTH gene transcription (Silver, et al.1986, Silver, et al.1985). Naveh-
Many, et al. (1995) studied rats with experimental uremia and 
showed that there was an increase in PT cells  
proliferation compared with control rats. Similar results were found 
by (Yi ,et al. 1995), who showed that rats with experimental uremia 
had an increase in serum PTH, PTH mRNA, and PT cell proliferation, 
all of which were prevented by mild dietary phosphorus restriction. 
1,25(OH)2D3 may have a role in regulating PT cell proliferation in 
chronic renal failure in addition to its role in decreasing PTH gene 
transcription. Szabo et al., (1989) showed that the thymidine 
incorporation into isolated PT glands from uremic rats was decreased 
by prior treatment with 1,25(OH)2D3.Cozzolino, et al. (2001) showed 
that the PT cell hyperplasia in rats with experimental chronic renal 
failure was decreased by a high dietary Ca2+ or treatment with 
1,25(OH)2D3. In this study, hypercalcemia was observed in 22.5% of 
patients with chronic renal failure. This hypercalcaemia may be due 
to the treatments used for the correction of hypocalcaemia, these 
medicines contain calcium supplementation, phosphate binders and 
active vitamin D sterols in various combination this agree with 
Quarles et al., (2003) who mentioned that usage of vitamin D and 
calcium for the treatment of hyperparathyroidism lead to the 
elevation of calcium and phosphorus levels.     
  
CONCLUSION 
 
It is concluded from this study that chronic renal failure 
results in hyper-parathyroidism. Also hypocalcaemia and hyper-
phosphataemia were presented. 
Age and duration of dialysis were found to have no effects on 
the PTH concentration.   
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QUESTIONNAIRE 
The PHT in haemodialysis Patients 
(1) Personal data:  
  Name: ……………………………………….. Age:……………………. 
  Sex ………... Residence: ……..…………….. Occupation:……………. 
(2) Duration of CRF :   
(1) 1-6 months                    (2) 1 year               (3) 2 year      
 (4) more than 3 years 
(3) Type of diet:  
(1) Proteins           (2) Carbohydrates            (3) Vitamins        
 (4) Others                   …………………………………………..     
(4) Number of dialysis per week: 
(1) One                      (2) Two                    (3) three  
(5) BP.   (1) Increase                (2) Decreased            (3) Normal 
(6) Past medical history: 
(1) Glomerulonephritis                       (2) DM             
 (3)Hypertension                                (4) Chronic pyelonephritis 
(5) Unknown  
(7) General symptoms:    (1) Bone pain                     (2)   Muscle pain 
                                            (3) Fracture                      (4) Others: …………………    
(8) Treatment:     …………………………………………………………………. 
 (9) Investigation: (1) PTH ………………. (.2) Total calcium…………  
                                  (.3) Phosphorus…………...  
(10) Other notes:……………………………………...…………………………… 
  
  
 
  
Table (3): The distribution of age in the study population (n = 40) 
Years  Frequency  % 
1 – 20  2 5 
21 – 40  13 32.5 
41 – 60  22 55 
61 – 80  3 7.5 
Total  40 100 % 
 
 
 
 
 
Fig. (6): Distribution of sex in the study population
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Fig. 7.  Distribution of duration of dialysis in the study 
population  
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